 |
|
|
| |
STARTVerso 4: High rates of early virologic response in HCV genotype 1/HIV-co-infected patients treated with faldaprevir plus pegIFN and RBV
|
| |
| |
Reported by Jules Levin
20th Conference on Retroviruses and Opportunistic Infections, March 3-6, 2013
Douglas Dieterich,1 Vicente Soriano,2 Mark Nelson,3
Jurgen Kurt Rockstroh,4 Keikawus Arasteh,5 Sanjay Bhagani,6
Andrew Talal,7 Cristina Tural,8 Richard Vinisko,9 and Jens Kort 9
1Mount Sinai School of Medicine, New York, NY, USA; 2Hospital Carlos III, Madrid, Spain; 3Chelsea and Westminster Hospital, London, UK; 4University of Bonn, Bonn, Germany; 5EPIMED, Vivantes Auguste-Viktoria Hospital, Berlin, Germany; 6Royal Free Hospital, London, UK; 7State University of New York, Buffalo, NY, USA; 8Hospital Universitari Germans Trias i Pujol, Barcelona, Spain; 9Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
|
| |
|
|
|
|
|
